SurvivorNet

Someone, right now, is typing "stage 3" into a search bar

It is 2am somewhere. A person just heard three words from a doctor and now they are alone with a glowing screen, typing a sentence they never wanted to write. The results come back: a forum from 2011, an ad for a supplement, a hospital page written for other doctors, and a headline engineered to scare. This is the moment SurvivorNet was built for.

SurvivorNet is a New York media company that does one stubborn thing: it makes cancer information that an oncologist would actually stand behind, and then it makes that information watchable. Roughly 2.5 million people land on it every month. Most of them are scared. Most of them leave knowing a little more about what to ask next. That is the entire product, and it is harder than it sounds.

Pictured above: not a hospital, not a lab - a logo. Which is sort of the point. SurvivorNet is media, not medicine, and it knows the difference.

The internet had an opinion about your cancer. It was usually wrong.

Health information online has always been a strange marketplace. The loudest voices are rarely the most qualified, and the most qualified are rarely the easiest to read. For a person facing cancer, that combination is not an inconvenience - it shapes decisions about treatment, about second opinions, about whether to travel for care at all.

Here is the statistic that haunts the whole enterprise: roughly 70% of Americans are treated for cancer outside the major comprehensive cancer centers, where, for many cancers, outcomes are measurably better. The gap between "the care available at MD Anderson" and "the care available down the road" is partly a gap in information - what trials exist, what questions to ask, what the standard of care even is.

You can build a clinic to fix part of that gap. SurvivorNet's bet was that you could also build a newsroom.

A network producer and a healthcare VC walk into a diagnosis

Steve Alperin spent years inside ABC News, including as a senior producer on Peter Jennings' flagship broadcast. He knew how to take something complicated and make it land on a screen. Then his father was diagnosed with cancer, and Alperin discovered that all that production skill was useless against the actual problem: nobody had made the clear, trustworthy version of the information his family needed.

He partnered with Tim Langloss, a healthcare venture capitalist whose track record includes backing Optune, one of the few genuinely new brain-cancer treatments, through the public company Novocure. One co-founder understood storytelling; the other understood the science and the business of treatment. In 2018 they launched SurvivorNet on a simple premise: pair broadcast-quality video with content vetted by the country's top oncologists, and give it away to patients.

Two founders, one grief, zero interest in publishing another listicle about "10 superfoods that fight cancer."

Less "blog," more "newsroom with a medical board"

SurvivorNet is not one thing - it is a small stack of tools that all point at the same goal: a better-informed patient. The flagship is the website itself, organized by cancer type and reviewed in collaboration with oncologists, so that a person can move from "what is this" to "what should I ask" without wading through fear-bait.

The Clinical Trial Finder does the thing every patient dreads doing alone: reading 100,000 trials so you don't have to.

Numbers that grew the way trust grows: slowly, then a lot

The strongest evidence that SurvivorNet works is that people keep coming back, and serious institutions keep signing on. Editorial collaborations span the names that anchor American oncology - MD Anderson, Memorial Sloan Kettering, Mayo Clinic, Cleveland Clinic, Stanford, Cedars-Sinai, Dana-Farber and the National Cancer Institute. NYU Langone's Perlmutter Cancer Center joined the trial platform for a pancreatic cancer initiative.

That growth is not a vanity metric. Every additional visitor is, statistically, someone who might otherwise have been stuck with the forum from 2011 and the supplement ad. The Independa partnership pushed SurvivorNetTV onto millions of LG smart TVs, which matters more than it sounds: a meaningful share of cancer patients are older, less comfortable hunting through search results, and far more at home with a remote control than a chat box. Meeting them on the living-room screen is not a marketing flourish; it is access by another route.

The institutional roster does double duty, too. When a name like Memorial Sloan Kettering or the National Cancer Institute is attached to the editorial process, it does the quiet work of credibility - the thing no amount of clever copywriting can manufacture. For a category drowning in confident-sounding misinformation, "vetted by the people who actually treat this" is the rarest claim on the internet.

Democratize the information, not just the empathy

Plenty of organizations offer cancer patients comfort. SurvivorNet's stated mission is narrower and, in a way, more radical: give every patient the same quality of information that patients at top cancer centers receive, regardless of zip code or background. Comfort is the tone; access is the product.

That is why the editorial process leans on oncologists rather than influencers, why the trial finder is built on the public clinicaltrials.gov database rather than a walled garden, and why the whole thing stays free to patients while the business runs on advertising, sponsorship and healthcare partnerships. The model funds the mission instead of fighting it.

A 24-person team in SoHo, quietly running a newsroom for the conversation nobody wants to have.

AI made the noise louder. It also made the answer possible.

The same technology that floods the internet with plausible-sounding nonsense is the technology SurvivorNet is using to cut through it - matching patients to trials, helping them frame their own questions, scaling expert-vetted answers to millions. The risk and the remedy are the same tool, which is exactly why it matters who is holding it.

If SurvivorNet is right, the next decade looks like this: information stops being the part of cancer care that patients have to fend for themselves. The trial that exists for your condition finds you, instead of the other way around. The standard of care travels, even when the patient can't.

So go back to that glowing screen at 2am. The person is still scared - that part SurvivorNet can't fix. But now the first result is not a supplement ad. It is a clearly produced video, reviewed by an oncologist, that says: here is what this means, here is what to ask, and here are the trials near you. The screen is the same. What's on it is not.